Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.52 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26454425 | 0.84 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL19599017 | 0.84 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL1390600 | 0.84 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL1710059 | 0.84 | RAB9A (0.68) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL2529345 | 0.82 | ALDH1A1 (0.62) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL974755 | 0.82 | ALDH1A1 (0.62) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL2527782 | 0.82 | ALDH1A1 (0.62) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL23054249 | 0.81 | RAB9A (0.54) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL21051399 | 0.81 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL21051390 | 0.81 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022120207-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-15 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| WO-2007042660-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | POLRMT, POLR1C, FBL | NPC1 3918/4885RAB9A 3913/4885SMN1; SMN2 3912/4885 |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | NPC1 1164/4885RAB9A 2174/4885SMN1; SMN2 2592/4885 |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | NPC1 882/4885RAB9A 328/4885SMN1; SMN2 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.